{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:19:52Z","timestamp":1792430392401,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jclinepi.2025.112097","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:34:03Z","timestamp":1764894843000},"page":"112097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Comparison between risk of bias-1 and risk of bias-2 tool and impact on network meta-analysis results\u2014A case study from a living Cochrane review on psoriasis"],"prefix":"10.1016","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4044-0727","authenticated-orcid":false,"given":"R.","family":"Guelimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2639-0958","authenticated-orcid":false,"given":"C.","family":"Ollivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Beytout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0560-5493","authenticated-orcid":false,"given":"Q.","family":"Samaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mubuangankusu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Chaimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sbidian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2791-223X","authenticated-orcid":false,"given":"S.","family":"Afach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1385-6839","authenticated-orcid":false,"given":"L.","family":"Le Cleach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jclinepi.2025.112097_bib1","series-title":"Cochrane handbook for systematic reviews of interventions version 6.5","article-title":"Chapter 8: Assessing risk of bias in a randomized trial","author":"Higgins","year":"2024"},{"key":"10.1016\/j.jclinepi.2025.112097_bib2","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2025.112097_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.jclinepi.2025.112097_bib4","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jclinepi.2012.07.005","article-title":"Testing the risk of bias tool showed low reliability between individual reviewers and across consensus assessments of reviewer pairs","volume":"66","author":"Hartling","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.jclinepi.2025.112097_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017242","article-title":"Applying the risk of bias tool in a systematic review of combination long-acting beta-agonists and inhaled corticosteroids for persistent asthma","volume":"6","author":"Hartling","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jclinepi.2025.112097_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b4012","article-title":"Risk of bias versus quality assessment of randomised controlled trials: cross sectional study","volume":"339","author":"Hartling","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.112097_bib7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12874-019-0804-y","article-title":"Risk of bias judgments for random sequence generation in Cochrane systematic reviews were frequently not in line with Cochrane Handbook","volume":"19","author":"Barcot","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jclinepi.2025.112097_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jclinepi.2019.04.007","article-title":"Risk of bias assessments for selective reporting were inadequate in the majority of Cochrane reviews","volume":"112","author":"Saric","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2025.112097_bib9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jclinepi.2018.10.002","article-title":"In Cochrane reviews, risk of bias assessments for allocation concealment were frequently not in line with Cochrane's Handbook guidance","volume":"106","author":"Propadalo","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2025.112097_bib10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13643-016-0259-8","article-title":"Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews","volume":"5","author":"J\u00f8rgensen","year":"2016","journal-title":"Syst Rev"},{"issue":"7","key":"10.1016\/j.jclinepi.2025.112097_bib11","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"7","author":"Sbidian","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.jclinepi.2025.112097_bib12","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"8","author":"Sbidian","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jclinepi.2025.112097_bib13","series-title":"Cochrane handbook for systematic reviews of interventions version 5.2.0","article-title":"Chapter 8: Assessing risk of bias in included studies","author":"Higgins","year":"2017"},{"key":"10.1016\/j.jclinepi.2025.112097_bib14","author":"Guelimi"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.112097_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"issue":"535","key":"10.1016\/j.jclinepi.2025.112097_bib16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1192\/bjp.116.535.651","article-title":"Comparing the classification of subjects by two independent judges","volume":"116","author":"Maxwell","year":"1970","journal-title":"Br J Psychiatry"},{"issue":"244","key":"10.1016\/j.jclinepi.2025.112097_bib17","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1080\/01621459.1948.10483284","article-title":"A test for symmetry in contingency tables","volume":"43","author":"Bowker","year":"1948","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"10.1016\/j.jclinepi.2025.112097_bib18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2025.112097_bib19","author":"Gamer"},{"key":"10.1016\/j.jclinepi.2025.112097_bib20","author":"R\u00fccker"},{"key":"10.1016\/j.jclinepi.2025.112097_bib21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jclinepi.2021.09.021","article-title":"Reliability of the revised cochrane risk-of-bias tool for randomised trials (RoB2) improved with the use of implementation instruction","volume":"141","author":"Minozzi","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2025.112097_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jclinepi.2020.06.015","article-title":"The revised cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application","volume":"126","author":"Minozzi","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2025.112097_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jclinepi.2023.06.015","article-title":"Risk-of-bias assessment using Cochrane's revised tool for randomized trials (RoB 2) was useful but challenging and resource-intensive: observations from a systematic review","volume":"161","author":"Crocker","year":"2023","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.jclinepi.2025.112097_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096920","article-title":"Poor reliability between cochrane reviewers and blinded external reviewers when applying the cochrane risk of bias tool in physical therapy trials","volume":"9","author":"Armijo-Olivo","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.112097_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.112097_bib26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jclinepi.2025.112097_bib27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.14412\/1996-7012-2018-4-71-84","article-title":"Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2\/CALYPSO phase III international, multicenter, randomized double-blind clinical trial","volume":"12","author":"Korotaeva","year":"2018","journal-title":"Mod Rheumatol J"},{"issue":"6","key":"10.1016\/j.jclinepi.2025.112097_bib28","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40259-021-00502-w","article-title":"Efficacy, safety and immunogenicity of AVT02 versus originator adalimumab in subjects with moderate to severe chronic plaque psoriasis: a multicentre, double-blind, randomised, parallel group, active control, phase III study","volume":"35","author":"Feldman","year":"2021","journal-title":"BioDrugs"},{"key":"10.1016\/j.jclinepi.2025.112097_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111406","article-title":"Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a cochrane systematic review","volume":"173","author":"Beytout","year":"2024","journal-title":"J Clin Epidemiol"},{"issue":"19","key":"10.1016\/j.jclinepi.2025.112097_bib30","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1001\/archinternmed.2009.306","article-title":"Reporting of safety results in published reports of randomized controlled trials","volume":"169","author":"Pitrou","year":"2009","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.jclinepi.2025.112097_bib31","doi-asserted-by":"crossref","first-page":"502","DOI":"10.5694\/mja2.51755","article-title":"Strengthening the reporting of harms of all interventions in clinical trials","volume":"217","author":"Abdel","year":"2022","journal-title":"Med J Aust"},{"key":"10.1016\/j.jclinepi.2025.112097_bib32","author":"Richter"},{"key":"10.1016\/j.jclinepi.2025.112097_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jclinepi.2019.11.008","article-title":"Overall bias methods and their use in sensitivity analysis of cochrane reviews were not consistent","volume":"119","author":"Babic","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2025.112097_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jclinepi.2022.09.003","article-title":"Adherence of systematic reviews to cochrane RoB2 guidance was frequently poor: a meta epidemiological study","volume":"152","author":"Minozzi","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.jclinepi.2025.112097_bib35","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/jrsm.1695","article-title":"Frequency of use and adequacy of Cochrane risk of bias tool 2 in non-Cochrane systematic reviews published in 2020: Meta-research study","volume":"15","author":"Babi\u0107","year":"2024","journal-title":"Res Synth Methods"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435625004305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435625004305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T19:11:55Z","timestamp":1770059515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435625004305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":35,"alternative-id":["S0895435625004305"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2025.112097","relation":{},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison between risk of bias-1 and risk of bias-2 tool and impact on network meta-analysis results\u2014A case study from a living Cochrane review on psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2025.112097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112097"}}